MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

Search

Allogene Therapeutics Inc

Ouvert

SecteurSoins de santé

1.57 -1.26

Résumé

Variation du prix de l'action

24h

Actuel

Min

1.52

Max

1.59

Chiffres clés

By Trading Economics

Revenu

6.4M

-60M

BPA

-0.28

Employés

226

EBITDA

6.8M

-56M

Recommandations

By TipRanks

Recommandations

Achat Fort

Prévisions sur 12 Mois

+441.4% upside

Dividendes

By Dow Jones

Prochains Résultats

12 mai 2025

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

-149M

309M

Ouverture précédente

2.83

Clôture précédente

1.57

Score Technique

By Trading Central

Confiance

Strong Bullish Evidence

Allogene Therapeutics Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

24 avr. 2025, 23:54 UTC

Actions en Tendance

Stocks to Watch: Alphabet, Intel, AppFolio

24 avr. 2025, 23:51 UTC

Market Talk

Gold Edges Higher, Supported by U.S. Dollar Weakness -- Market Talk

24 avr. 2025, 23:46 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

24 avr. 2025, 23:46 UTC

Market Talk

Nikkei May Rise on Hopes for Easing U.S.-China Trade Tensions -- Market Talk

24 avr. 2025, 23:37 UTC

Actualités

Big Tech Braces for Tariff-Induced Advertising Slowdown -- WSJ

24 avr. 2025, 23:36 UTC

Actualités

Tokyo Consumer Inflation Accelerates in April as Companies Raise Prices

24 avr. 2025, 23:13 UTC

Actualités
Résultats

Google's Earnings Power Holds Up in Global Turbulence -- Update

24 avr. 2025, 23:09 UTC

Actualités

Trump Initiatives Knocked Back in a New Round of Court Rulings -- 2nd Update

24 avr. 2025, 23:02 UTC

Acquisitions, Fusions, Rachats

SK Telecom to Sell 10.8M Kakao Shares via After-Hours Block Trading

24 avr. 2025, 23:02 UTC

Acquisitions, Fusions, Rachats

SK Telecom to Dispose of 2.4% Stake in Kakao to Raise KRW413.27B

24 avr. 2025, 22:51 UTC

Actualités
Acquisitions, Fusions, Rachats

Germany's Merck Nears Roughly $3.5 Billion Deal for SpringWorks -- Update

24 avr. 2025, 22:48 UTC

Actualités

Walmart Walks the DEI Tightrope in Latest Proxy Statement -- Barrons.com

24 avr. 2025, 22:47 UTC

Market Talk

Intel Remains in Tough Position, CFRA Research Analyst Says -- Market Talk

24 avr. 2025, 22:38 UTC

Market Talk
Résultats

Tariffs Hurt Intel's 2Q Outlook as CFO Warns Economic Slowdown is Likely -- Market Talk

24 avr. 2025, 22:24 UTC

Résultats

Aluminum Corp. of China: Increase in Product Sales Supported 1Q Results >2600.HK

24 avr. 2025, 22:24 UTC

Résultats

Aluminum Corp. of China 1Q Rev CNY55.78B Vs. CNY48.96B >2600.HK

24 avr. 2025, 22:24 UTC

Market Talk
Résultats

Intel's Comeback Involves More Engineers, More In-Office Work -- Market Talk

24 avr. 2025, 22:23 UTC

Résultats

Aluminum Corp. of China 1Q Net CNY3.54B Vs. Net CNY2.23B >2600.HK

24 avr. 2025, 22:11 UTC

Market Talk
Résultats

Global Equities Roundup: Market Talk

24 avr. 2025, 22:11 UTC

Market Talk
Résultats

Intel CEO: Layoffs Will Simplify Company Structure -- Market Talk

24 avr. 2025, 22:09 UTC

Actualités
Résultats

Intel Cuts Outlook, Says Layoffs Are in Store -- Update

24 avr. 2025, 22:00 UTC

Market Talk
Résultats

T-Mobile's Key Subscriber Metric Disappoints Despite Earnings Beat -- Market Talk

24 avr. 2025, 21:39 UTC

Actualités

Trump Initiatives Knocked Back in a New Round of Court Rulings -- WSJ

24 avr. 2025, 21:24 UTC

Actualités
Résultats

Bristol Myers Reports Better-Than-Expected Earnings. The Future Is Cloudy. -- Barrons.com

24 avr. 2025, 21:24 UTC

Actualités
Résultats

Google's Earnings Power Holds Up in Global Turbulence -- WSJ

24 avr. 2025, 21:23 UTC

Actualités
Résultats

Intel Cuts Outlook, Says Layoffs Are in Store -- WSJ

24 avr. 2025, 21:04 UTC

Résultats

T-Mobile Reports Strong Earnings but Its Wireless Results Disappoint. The Stock Is Sliding. -- Barrons.com

24 avr. 2025, 21:03 UTC

Résultats

Agnico-Eagle Mines Believes Its Rev Structure Will Be Largely Unaffected by the Tariffs >AEM.T

24 avr. 2025, 21:03 UTC

Résultats

Agnico-Eagle Mines Total Expected Capex for 2025 Still Estimated at $1.75 B to $1.95 B >AEM.T

24 avr. 2025, 21:02 UTC

Résultats

Agnico-Eagle Mines Positioned to Achieve 2025 AISC Per Ounce Guidance of $1,250 to $1,300. >AEM.T

Comparaison

Variation de prix

Allogene Therapeutics Inc prévision

Objectif de Prix

By TipRanks

441.4% hausse

Prévisions sur 12 Mois

Moyen 8.5 USD  441.4%

Haut 14 USD

Bas 4 USD

Basé sur 12 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat Fort

12 ratings

11

Achat

1

Maintien

0

Vente

Score Technique

By Trading Central

1.45 / 1.59Support & Résistance

Court Terme

Strong Bullish Evidence

Moyen Terme

Weak Bullish Evidence

Long Terme

Bearish Evidence

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Allogene Therapeutics Inc

Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL). The company also develops cemacabtagene ansegedleucel, an engineered allogeneic CAR T cell product candidate that targets CD19 for the treatment of large B-cell lymphoma; and is in Phase 1b clinical trial for the treatment of chronic lymphocytic leukemia. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase 1 clinical trial for treating R/R multiple myeloma; ALLO-605, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; ALLO-316, an allogeneic CAR T cell product candidate that is in Phase 1 clinical trial for the treatment of advanced or metastatic RCC; ALLO-329 for the treatment of certain autoimmune diseases; DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors; and Claudin 18.2 for the treatment of gastric and pancreatic cancer. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates; and a strategic partnership with Foresight Diagnostics to develop MRD-based In-Vitro Diagnostic for use in ALPHA3. The company was incorporated in 2017 and is headquartered in South San Francisco, California.